Effect of Pneumococcal Conjugate Vaccine on Pneumonia Incidence Rates among Children 2–59 Months of Age, Mongolia, 2015–2021

Starting in June 2016, the 13-valent pneumococcal conjugate vaccine (PCV13) was introduced into the routine immunization program of Mongolia by using a 2+1 dosing schedule, phased by district. We used prospective hospital surveillance to evaluate the vaccine's effect on pneumonia incidence rate...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Emerging infectious diseases Ročník 30; číslo 3; s. 490 - 498
Hlavní autoři: von Mollendorf, Claire, Ulziibayar, Munkhchuluun, Nguyen, Cattram D., Batsaikhan, Purevsuren, Suuri, Bujinlkham, Luvsantseren, Dashtseren, Narangerel, Dorj, de Campo, John, de Campo, Margaret, Tsolmon, Bilegtsaikhan, Demberelsuren, Sodbayar, Dunne, Eileen M., Satzke, Catherine, Mungun, Tuya, Mulholland, E. Kim
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States U.S. National Center for Infectious Diseases 01.03.2024
Centers for Disease Control and Prevention
Témata:
Age groups
Air pollution
bacteria
children
Conjugate vaccines
Consent
Disease
Effect of Pneumococcal Conjugate Vaccine on Pneumonia Incidence Rates among Children 2–59 Months of Age, Mongolia, 2015–2021
hospitalization
Hospitals
Households
Immunization
Outdoor air quality
Pandemics
Patient outcomes
PCV13
Pediatric research
pneumococcal conjugate vaccine
Pneumococcal vaccine
Pneumonia
Pneumonia in children
Population
Prevention
Statistics
Streptococcus infections
Vaccines
Mongolia
Australia
Asia
Mongolia
PCV13
bacteria
hospitalization
pneumonia
children
respiratory infections
pneumococcal conjugate vaccine
ISSN:1080-6040, 1080-6059, 1080-6059
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Starting in June 2016, the 13-valent pneumococcal conjugate vaccine (PCV13) was introduced into the routine immunization program of Mongolia by using a 2+1 dosing schedule, phased by district. We used prospective hospital surveillance to evaluate the vaccine's effect on pneumonia incidence rates among children 2-59 months of age over a 6-year period. Of 17,607 children with pneumonia, overall adjusted incidence rate ratios showed decreased primary endpoint pneumonia, very severe pneumonia, and probable pneumococcal pneumonia until June 2021. Results excluding and including the COVID-19 pandemic period were similar. Pneumonia declined in 3 districts that introduced PCV13 with catch-up campaigns but not in the 1 district that did not. After PCV13 introduction, vaccine-type pneumococcal carriage prevalence decreased by 44% and nonvaccine-type carriage increased by 49%. After PCV13 introduction in Mongolia, the incidence of more specific pneumonia endpoints declined in children 2-59 months of age; additional benefits were conferred by catch-up campaigns.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1080-6040
1080-6059
1080-6059
DOI:10.3201/eid3003.230864